When will sertraline (selective serotonin reuptake inhibitor) reach its peak plasma concentration in a typical adult patient with depression or anxiety?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 16, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

When Sertraline Reaches Peak Plasma Concentration

Sertraline reaches peak plasma concentration between 4.5 to 8.4 hours after oral administration, with most studies reporting peak levels at approximately 6-8 hours post-dose. 1, 2

Pharmacokinetic Profile

Absorption and Peak Timing

  • Peak plasma concentrations (Cmax) occur between 4.5 to 8.4 hours after oral dosing when administered once daily over the therapeutic range of 50 to 200 mg for 14 days 1
  • Research studies consistently report peak levels at 6-8 hours post-administration in clinical populations 2
  • Sertraline is slowly absorbed following oral administration, which accounts for the delayed time to peak concentration 3

Food Effects on Absorption

  • Food slightly prolongs the time to peak concentration from 5.9 hours to 7 hours when sertraline oral concentrate is administered with meals 1
  • Despite this delay, food does not significantly alter overall bioavailability 1

Time to Steady-State Concentrations

Accumulation Pattern

  • Steady-state plasma levels are achieved after approximately one week (7 days) of once-daily dosing, based on the terminal elimination half-life of about 26 hours 1
  • There is approximately two-fold accumulation of sertraline with repeated dosing compared to single-dose administration over the 50 to 200 mg dose range 1
  • The elimination half-life ranges from 22-36 hours, supporting once-daily therapeutic dosing 3

Active Metabolite Considerations

  • N-desmethylsertraline (the primary metabolite) has a much longer elimination half-life of 62 to 104 hours 1
  • This metabolite exhibits 5 to 9-fold increases in pharmacokinetic parameters between day 1 and day 14, accumulating to greater concentrations than the parent drug at steady state 1, 3
  • However, N-desmethylsertraline is substantially less active than sertraline itself 1

Clinical Implications

Therapeutic Onset

  • While peak plasma concentrations occur within hours, beneficial effects on core depression and anxiety symptoms appear as early as 2 weeks of treatment 4
  • The general pharmacokinetic properties of antidepressants show maximum plasma concentration within 0.5 to 4 hours, though sertraline falls on the slower end of this spectrum 5

Dosing Considerations

  • Linear dose-proportional pharmacokinetics were demonstrated, meaning Cmax and AUC are proportional to dose over the 50 to 200 mg range 1
  • Once-daily administration is therapeutically effective due to the relatively long elimination half-life 3, 2

Important Caveats

  • Steady-state plasma concentrations vary widely (up to 15-fold) in patients receiving usual antidepressant dosages between 50 and 150 mg/day 3
  • There is minimal correlation between sertraline plasma concentrations and therapeutic or adverse effects, making routine therapeutic drug monitoring generally unnecessary 3, 6
  • The pharmacokinetics in elderly patients and those with renal impairment are similar to young healthy volunteers, though young males may have lower peak concentrations and shorter elimination half-lives 2

References

Research

Clinical implications of the pharmacology of sertraline.

International clinical psychopharmacology, 1991

Research

Clinical pharmacokinetics of sertraline.

Clinical pharmacokinetics, 2002

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Clinical outcome and tolerability of sertraline in major depression: a study with plasma levels.

Progress in neuro-psychopharmacology & biological psychiatry, 2002

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.